ESMO Gastrointestinal Cancers Congress | Conference

Novel Bispecific Antibody Effective for Heavily Pretreated mCRC

July 1st 2017

CEA-TCB showed a favorable safety profile and promising efficacy in patients with heavily-pretreated microsatellite stable metastatic colorectal cancer, with enhanced efficacy when combined with atezolizumab.

Liquid Biopsies Identify Mechanisms of Resistance in Gastrointestinal Cancers

July 1st 2017

Aparna Parikh, MD, discusses the potential impact of liquid biopsies in overcoming resistance to targeted therapies in gastrointestinal cancer.

Occurrence of Hand-Foot Skin Response May Signal Regorafenib Activity in Hepatocellular Carcinoma

June 30th 2017

Patients with unresectable HCC continue to show statistically significant improvement in overall survival with second-line regorafenib (Stivarga) treatment.

Advanced Age Presents No Barrier to Successful Nivolumab Treatment in HCC

June 30th 2017

Durable responses and improved long-term survival were demonstrated with nivolumab (Opdivo) that were not altered by the age of patients with advanced hepatocellular carcinoma across all age groups of patients participating in the CheckMate 040 trial.

Dr. Saab on Napabucasin With Gemcitabine and Nab-Paclitaxel in Pancreatic Adenocarcinoma

June 30th 2017

Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses napabucasin with gemcitabine and nab-paclitaxel in pancreatic adenocarcinoma.

Dr. Parikh Discusses Liquid Biopsies in Gastrointestinal Cancers

June 30th 2017

Aparna R. Parikh, MD, medical oncologist, Massachusetts General Hospital, discusses liquid biopsies in gastrointestinal cancers.

Expert Discusses Tumor Location and Mutational Status in CRC

June 30th 2017

Julien Taieb, MD, discusses the prognostic value of primary tumor location in colon cancer.

HA Levels Predict PEGPH20 Response in Metastatic Pancreatic Cancer

June 29th 2017

The addition of pegvorhyaluronidase alfa (PEGPH20) to standard nab-paclitaxel/gemcitabine improved progression-free survival over standard therapy in patients with metastatic pancreatic ductal adenocarcinoma.

Dr. Hendifar on the HALO-202 Study in Metastatic Pancreatic Ductal Adenocarcinoma

June 29th 2017

Andrew E. Hendifar, MD, medical oncology lead for the Gastrointestinal Disease Research Group, Cedars-Sinai Medical Center, discusses HALO-202 in metastatic pancreatic ductal adenocarcinoma.

Dr. Bruix Discusses the Updated Findings of the RESORCE Trial in HCC

June 29th 2017

Jordi Bruix, MD, head of the Barcelona Clinic Liver Cancer (BCLC) at University of Barcelona, discusses the updated findings of the RESORCE Trial in hepatocellular carcinoma.

AM0010 Plus FOLFOX Shows Promise in Metastatic Pancreatic Cancer

June 29th 2017

Combination therapy with AM0010, a PEGylated human interleukein (IL)-10, plus fluorouracil (5-FU), leucovorin, and oxaliplatin (FOLFOX) demonstrated encouraging clinical activity in metastatic pancreatic ductal adenocarcinoma.

Dr. Heinemann on the Use of Depth of Response and RECIST in CRC

October 24th 2016

Volker Heinemann, MD, PhD, director of the Comprehensive Cancer Center at Ludwig Maximilian University of Munich, compares the use of depth of response and RECIST criteria to measure responses in patients with colorectal cancer.

Dr. Dicato on Agents to Treat Thrombocytopenia for Patients With Cancer

July 21st 2016

Mario Dicato, MD, Hematology-Oncology Service, Centre Hospitalier de Luxembourg, discusses 3 agents used for the treatment or reduction of thrombocytopenia for patients with cancer.

Dr. Strosberg on Pasireotide for Neuroendocrine Tumors

July 20th 2016

Jonathan R. Strosberg, MD, associate professor at H. Lee Moffitt Cancer Center, discusses pasireotide as a potential treatment for patients with neuroendocrine tumors.

Dr. Pietrantonio on Nomogram to Predict Survival Rates in CRC

July 20th 2016

Filippo Pietrantonio, MD, Department of Medical Oncology, Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan Fondazione IRCCS Istituto Nazionale dei Tumori, discusses findings of a clinical trial examining a nomogram used to predict 12-week survival rates for patients with colorectal cancer (CRC).

Dr. Ilson on the Future Treatment Paradigm of Gastric Cancers

July 19th 2016

David H. Ilson, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses how the treatment paradigm of gastric cancers will evolve in the future.

Dr. Sharma on Results of SIRFLOX Study for CRC

July 14th 2016

Navesh K. Sharma, DO, PhD, associate professor of Radiology in the Division of Radiology and Oncology at Penn State Hershey Medical Center and section chief of Radiation Oncology at the Penn State Health St. Joseph Cancer Center, discusses the results of the SIRFLOX study, which examined the addition of Yttrium-90 (Y-90) resin microspheres (SIR-Spheres) to standard frontline FOLFOX-based chemotherapy with or without bevacizumab for patients with liver metastatic colorectal cancer (CRC).

Dr. Volker Heinemann on the Addition of SIRT to Chemotherapy for mCRC

July 8th 2016

Volker Heinemann, MD, PhD, director of the Comprehensive Cancer Center at Ludwig Maximilian University of Munich, discusses how depth of response, which is highly correlated with overall survival, was improved for patients with metastatic colorectal cancer who added selective internal radiation therapy (SIRT) to chemotherapy.

Dr. Daniele on Impact of Regorafenib in HCC

July 8th 2016

Bruno Daniele, MD, director, Department of Oncology and Medical Oncology, G. Rummo Hospital, Italy, discusses the potential impact of regorafenib (Stivarga) for the treatment of patients with hepatocellular carcinoma (HCC).

First-Line Cetuximab Combo Validated in RAS Wild-Type Colorectal Cancer

July 3rd 2016

The addition of cetuximab to standard FOLFOX-4 chemotherapy in the first-line treatment of patients with RAS wild-type metastatic colorectal cancer significantly improved survival outcomes.